Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice
Open Access
- 17 March 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Tumor infiltrating T cells (TIL) are key players in the anti-tumor immune response. However, chronic exposure to tumor-derived antigens drives the differentiation into ‘exhausted’ TILs. Whether intratumoral dendritic cells (DC) can mitigate TILs exhaustion and maintain function is unclear. Here, we develop a bispecific DC-T cell engager (BiDT), consisting of an anti-TIM3-IFN fusion protein, and demonstrate that, in preclinical mouse tumor models, this engager simultaneously targets TIM3 on exhausted TILs and activates DCs via the IFNAR receptor. Mechanistically, BiDT reactivates exhausted TIM3+TILs by preventing apoptosis through increased Bcl-2 expression and enhances DC function to reactivate T cells via IL-2 signalling and co-stimulatory CD80/86-CD28 interactions within the tumor microenvironment. Finally, to mitigate IFNα-induced toxicity, we engineer a Pro-BiDT engager featuring a pro-IFNα and report potent antitumor activity with reduced systemic toxicity. Thus, by bridging DC-T cells together, BiDT treatment enhances the critical communication pathways and cellular circuits necessary for effective anti-tumor immunity.Keywords
This publication has 51 references indexed in Scilit:
- PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategiesCancer Immunology, Immunotherapy, 2023
- Type I interferon-mediated tumor immunity and its role in immunotherapyCellular and Molecular Life Sciences, 2022
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer Cell, 2019
- T Cell Dysfunction in CancerCancer Cell, 2018
- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune ResponsesCancer Cell, 2014
- Matrix metalloproteinases and tumor metastasisCancer and Metastasis Reviews, 2006
- Side Effects of Interferon-α TherapyPharmacy World & Science, 2005
- CD28‐mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28European Journal of Immunology, 1997
- CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xLImmunity, 1995
- RAG-1-deficient mice have no mature B and T lymphocytesCell, 1992